[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589356":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":27,"locations":35,"responsibleParty":54,"collaborators":56,"id":60,"slug":10,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":10,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":17,"conditions":72,"keywords":74,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Barnet Dulaney Perkins Eye Centers","NETWORK",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single Group\u002FCohort retrospectively utilized",null,"This will be 300 eyes that have undergone the combination of Phacoemulsification, OMNI Canaloplasty and Hydrus microstent that will successfully lower IOP in ethnically-diverse patients with Open Angle Glaucoma",[13],"Procedure: Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis","The use of combination Phacoemulsification, OMNI Canaloplasty and Hydrus microstent successfully lowers IOP in ethnically-diverse patients with Open Angle Glaucoma",[9],[21,22],"OMNI","Hydrus Microstent",[24],{"name":25,"affiliation":5,"role":26},"Christine Funke, Medical Doctor","PRINCIPAL_INVESTIGATOR",[28,33],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Derek J Arnson, Master of Education","CONTACT","4804201005","derek.arnson@researchavp.com",{"name":25,"role":30,"phone":31,"phoneExt":10,"email":34},"christine.funke@BDPEC.com",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Barnet Dulaney Perkins Eye Center","RECRUITING","Mesa","Arizona","85206","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-111.82264,33.42227,{"lat":48,"lon":47},[51,52,53],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},{"name":25,"role":30,"phone":31,"phoneExt":10,"email":34},{"name":25,"role":26,"phone":10,"phoneExt":10,"email":10},{"type":55,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[57],{"name":58,"class":59},"Alcon, a Novartis Company","INDUSTRY","100589356",false,"NCT06953349","Efficacy of Surgical Systems in Combination With Phacoemulsification: a Retrospective Analysis","Real-World Efficacy of Hydrus Microstent With OMNI Surgical System in Combination With Phacoemulsification: a Retrospective Analysis","Inclusion Criteria:\n\n* Subjects with h\u002Fo CEIOL\u002FOMNI\u002FHydrus (chosen based on subjects on more than 1 medication pre-operatively) with at least 3 years of follow up data\n* have Glaucoma\n\nExclusion Criteria:\n\n* Patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies.\n* Patients with refractory CME or CME persisting 3 months or more post-operatively\n* Patients with incomplete IOP, medication logs or VF data within post-operative period\n* Prior incisional surgery or MIGS","ALL","18 Years",{"count":69,"type":70},300,"ESTIMATED","OBSERVATIONAL",[73],"Open-Angle Glaucoma",[22,75,76],"OMNI Surgical System","Phacoemulsification","2025-04-29",{"date":79,"type":80},"2025-05-01","ACTUAL",{"date":82,"type":80},"2025-03-31",{"date":84,"type":70},"2025-12-31",{"name":5,"class":6},1]